πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

16 results for β€œchimeric” Clear

  1. Live attenuated Japanese encephalitis chimeric virus vaccine

    Sanofi Pasteur

    Japanese Encephalitis

    phase 3 mab completed

    1 trial

  2. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  3. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  4. Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

    CytoMed Therapeutics Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  5. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Ξ³Ξ΄ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial

  6. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  7. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  8. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  9. CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

    The First People's Hospital of Lianyungang

    Refractory Idiopathic Membranous Nephropathy

    phase 1 small molecule active

    1 trial

  10. Chimeric antigen receptor T cell

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  11. Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumor

    phase 1 small molecule active

    1 trial

  12. JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

    Shanghai University of Traditional Chinese Medicine

    Diffuse Large B Cell Lymphoma

    phase 1 mab completed

    1 trial

  13. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

    phase 1 mab active

    1 trial

  14. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  15. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  16. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    T-ALL

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources